ExCellThera specializes in hematopoietic stem cell (HSC) expansion and rejuvenation through its proprietary Enhance™ platform, enabling the development of allogeneic stem cell therapies for blood cancers. The company addresses the need for effective treatments in hematological malignancies by enhancing the quantity and quality of stem cells used in therapeutic applications.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with hematological malignancies often require hematopoietic stem cell transplants, but the limited availability of suitable stem cells can restrict treatment options and outcomes. Current methods for expanding stem cell populations ex vivo often result in reduced cell quality and functionality, hindering the effectiveness of subsequent therapies.
Solution
ExCellThera offers the Enhance™ platform, a proprietary technology designed for the expansion and rejuvenation of hematopoietic stem cells (HSCs). This platform enables the development of allogeneic stem cell therapies by enhancing both the quantity and quality of HSCs. By improving the characteristics of stem cells used in therapeutic applications, ExCellThera aims to provide more effective treatments for blood cancers and other diseases. The platform's bioengineering solutions modify various cell lines for use in single-use curative therapies.
Target Audience
The primary target audience includes patients with hematological malignancies requiring stem cell transplants, as well as clinicians and researchers seeking to improve stem cell therapy outcomes.
Features
- Proprietary Enhance™ platform for HSC expansion and rejuvenation
- Bioengineering solutions to expand and modify various cell lines
- Focus on improving both the quantity and quality of stem cells
- Development of allogeneic stem cell therapies
- UM171 cell therapy for treating blood cancers
- Pre-clinical pipeline for blood cancers and other diseases